-+ 0.00%
-+ 0.00%
-+ 0.00%

Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $3

Benzinga·05/13/2025 17:14:05
Listen to the news
Benchmark analyst Bruce Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $4.5 to $3.